Skip to content
★ Sign in to follow
Imeik Technology Development Co.,Ltd. logo

Imeik Technology Development Co.,Ltd. Stock: price and insider trades · China

爱美客

CN·Mcap CN¥28.8BHealth Care

No insider purchase over the last 90 days. The latest, by 简军, was filed 18 Dec 2023.

Imeik Technology Development Co.,Ltd.: what insiders have been doing

Imeik Technology Development Co.,Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). Nothing new has been filed by managers of Imeik Technology Development Co.,Ltd. in twelve months, the latest record being from 18 December 2023.

Over the whole record (from 2021), the tally stands at 2 purchases and 5 sales.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.

Insider Decl.
7
Thresholds
n/a
Buy Volume
€1M
2 ops. · all time
Sell Volume
€45M
5 ops. · all time

Since the insiders bought

  • Filed 18 Dec 2023 · 1058 days ago · €324k
    +5.4%
    Entry CN¥195.57 · Close at T+365 CN¥206.06

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate Imeik Technology Development Co.,Ltd. Buy (bullish), based on 11 analysts. Average price target: CN¥131.94.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 4,708 of 26,911 companies
68.6
score / 100
Value
48
Quality
89
FCF yld4.0%
Earn yld4.5%
EV/EBITDA18.4x
ROE13%
Gross mgn93%
Net mgn53%
Debt/EBITDA0.2x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥95.30
Analyst consensus
11 analysts
Buy
CN¥94.00Target CN¥131.94(+38%)CN¥160.60
Income statement
RevenueCN¥2.5B
Gross profitCN¥2.3B93% margin
EBITDACN¥1.6B64% margin
Net incomeCN¥1.3B46.2% margin
Valuation
PER (trailing)26.4x
PER (forward)20.5x
P/Book3.6x
Beta0.61
Balance sheet & cash
Market capCN¥28.8B
Total debtCN¥253.1M
Free Cash FlowCN¥1.2B
Debt / Equity0%
Profitability & ownership
ROE13.4%
ROA7.7%
% insiders59.5%
% institutions5.6%
Last declaration on 18 December 2023
Declarations7 total
  • ▲
    董事Executives
    3M CNY10SZSE
    9,000 shares25.7% of flowA股XSHESZSE:173000007174932700
    Canonical exit: 17 Mar 2024 (T+90)
  • ▲
    董事Executives
    7M CNY14SZSE
    22,000 shares74.3% of flowA股XSHESZSE:173000007095764400
    Canonical exit: 14 Feb 2024 (T+90)
  • ▼
    董事Executives
    119M CNY11SZSE
    317,000 shares37.6% of flowA股XSHESZSE:173000005252823580
  • ▼
    董事Executives
    50M CNY21SZSE
    90,000 shares15.7% of flowA股XSHESZSE:173000005176845470
  • ▼
    监事Executives
    2M CNY27SZSE
    4,000 shares100.0% of flowA股XSHESZSE:173000005163094200
  • ▼
    董事Executives
    131M CNY11SZSE
    235,000 shares40.9% of flowA股XSHESZSE:173000005154683700
  • ▼
    董事Executives
    19M CNY8SZSE
    33,000 shares5.8% of flowA股XSHESZSE:173000005002510100

7 of 7 declarations

About Imeik Technology Development Co.,Ltd.

爱美客 is a company operating in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the development and marketing of skincare products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations